NCT06207305
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Carcinoma, +6 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Adenocarcinoma, Mucinous
Explore clinical trials studying Adenocarcinoma, Mucinous. Study availability and eligibility vary by location and protocol.
13 public trials
5 recruiting studies
Adenocarcinoma, Mucinous trial results
NCT07587268
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Appendiceal Adenocarcinoma, +16 more
- Locations
-
- City of Hope Medical Center Durate, California, United States
NCT05947838
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Appendiceal Adenocarcinoma, +6 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT06399757
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Adnexal Diseases, +46 more
- Locations
-
- City of Hope Duarte, California, United States
- City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
- Florida Cancer Specialists & Research Institute Sarasota, Florida, United States
- University of Michigan Ann Arbor, Michigan, United States
Recruiting
Genetics of Appendix Cancer Study
NCT05734430
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Appendiceal Adenocarcinoma, +28 more
- Locations
-
- Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
Not Yet Recruiting
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
NCT07665684
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Adenosquamous Carcinoma of the Pancreas, +20 more
- Locations
-
- Princess Margaret Cancer Centre Toronto, Ontario, Canada
Not Yet Recruiting
TLR9 Immunotherapy for Peritoneal Carcinomatosis
NCT07658196
- Conditions
- Abdominal Neoplasms, Adenocarcinoma, Adenocarcinoma, Mucinous, +18 more
- Locations
-
- Rhode Island and the Miriam Hospitals (Brown University Health) Providence, Rhode Island, United States
Completed
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT03108131
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Appendix Adenocarcinoma, +20 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Phase I Trial HIPEC With Nal-irinotecan
NCT04088786
- Conditions
- Adenocarcinoma, Adenocarcinoma, Mucinous, Adenoma, +26 more
- Locations
-
- University of Kentucky Lexington, Kentucky, United States
- Stony Brook University Cancer Center Stony Brook, New York, United States
Active, Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
- Conditions
- Acinar Cell Carcinoma, Adenocarcinoma, Adenocarcinoma of Lung, +207 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States